Answers are grounded in this paper and cite their sources.
Brodalumab is approved for the treatment of palmoplantar pustulosis (PPP)—a chronic, immune-mediated skin disease—in Japan. A recent phase 3 randomized clinical trial and its open-label extension evaluated the long-term efficacy and safety of brodalumab over 68 weeks, in Japanese patients with PPP. This case series details the cases of pyoderma gangrenosum (PG), a rare, neutrophilic dermatosis, that were reported during the trial. Clinical and histopathological findings were reviewed for five patients with PPP who developed PG during or after brodalumab treatment in the phase 3 trial and its 68-week extension. All affected patients were female and aged 40–70 years without any other PG-associated medical conditions. Development of PG was observed at 61–345 days after treatment initiation. Brodalumab was discontinued after onset of PG, except in case 3. Prednisolone treatment was administered, except in case 4, with all cases showing improvement. PG may present as a rare condition in patients receiving brodalumab for PPP; the detailed mechanisms remain unclear, but early recognition and appropriate management is crucial. The open-label extension study was registered as NCT04061252.
No takes yet. Share an insight, caveat, or question.
Okubo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: